Targeted therapies
are drugs or other substances that block the growth of unwanted cells and
pathogens by interfering with specific molecules ("molecular
targets") involved in the growth, progression, and spread of disease.
Targeted therapies are sometimes called molecularly targeted drugs, molecularly
targeted therapies, precision medicines, etc. The emerging field of target
therapeutics offers varied potential treatments. Target therapies involves a
wide range of therapies, such as, gene therapy, which uses genetic material to
alter cells (either in vivo or in vitro) to help cure disease , and stem cell
therapy, that can be obtained from a very initial stage in human development
and has the prospect to develop all the cell types in the human body. Targeted
therapies offer the possibility of finding a cure for diseases with significant
unmet needs, including orphan diseases and diseases having a high burden
globally.
Rise in the number
of newly diagnosed patients, rigorous research & development activities,
adverse side effects of conventional therapies, and a rise in public awareness
toward chronic illnesses across the world are the major factors driving the
growth of the global targeted therapeutics market. Additionally, favorable
reimbursement policies available in developed countries are projected to boost
the growth of the targeted therapeutics market. However, high cost of the
treatment, lack of favorable reimbursement schemes in developing economies,
unavailability of the treatment in the Asian and African countries, such as,
Thailand and the Philippines, and a shortage of skilled professionals are
likely to restrain the growth of the targeted
therapeutics market during the forecast period. Nevertheless, there are a
number of late-stage pipeline candidates that are expected to generate strong
annual revenue during the forecast period; for example, PD-1 inhibitor
durvalumab for bladder cancer, head and neck cancer, liver cancer, renal cell
carcinoma and the CDK-4 and -6 inhibitor abemaciclib for glioblastoma,
liposarcoma, and mantle-cell lymphoma. Newer CAR-T cell therapies,
Tisagenlecleucel-T and KTE-C19, are also expected to make an entry into the
market and generate blockbuster revenues.
The global targeted
therapeutics market can be segmented based on drug type, application type,
distribution channel, and region. In terms of drug type, the targeted
therapeutics market can be divided into monoclonal antibody therapeutics,
protein/peptide therapeutics, small molecule drugs, RNA interference, stem cell
therapy, and gene therapy. The monoclonal antibodies segment is likely to hold
the leading share of the market during the forecast period; there are currently
73 monoclonal antibodies (mAb) approved for various indications with the
purpose of extending the patient’s lifespan. The current market leader is
Humira, which generated revenue of US$ 18.4 Bn in 2017 across a number of
indications. Based on application, the market can be classified into
immunology, oncology, infectious diseases, and others. Oncology is projected to
be the leading segment of the market, in terms of market share, during the
forecast period due to the high prevalence of the disorder and high level of
use of immunotherapies in treatment regimes. Pharmaceutical companies worldwide
are focused on developing target therapies to combat cancer at all stages and
also for the treatment of the disease. In terms of the distribution channel,
the market can be categorized into drug stores, retail pharmacies, hospital
pharmacies, and online sales.
Geographically, the
global targeted therapeutics market can be segmented into five regions: North
America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America dominated the global market in 2016. Usage of targeted therapies
is high in North America primarily due to steady approval for new indications and
research undertakings and increasing geriatric population in the region.
According to the Immune Deficiency Foundation, currently around 55,000 people
in the U.S. with antibody deficiency receive primary immunodeficiency diseases
treatment. Expected launch of targeted therapies in immunology and oncology
that are presently in clinical trials in the U.S. is likely to boost the market
growth in the region. Europe is expected to be the second-leading market for
targeted therapeutics during the forecast period. Growth of the market in the
region can be attributed to availability of several biologic drugs, such as,
Rituxan, Humira, Enbrel, and others. The targeted therapeutics market in Asia
Pacific is expected to register significant growth during the forecast period
due to development of health care infrastructure, high disposable income of
people, rise in health and hygiene-related awareness, large untapped market
base, and economic development in the region.
Key players
operating in the global targeted therapeutics market include Novartis AG, Amgen,
Inc., Pfizer, Inc., GlaxoSmithKline plc., Merck & co., Sanofi, and
Bristol-Myers Squibb Company. Several companies are developing targeted
therapeutics. These include diversified companies developing targeted
therapeutics as a part of their broad product portfolio, to highly specialized
companies, focusing exclusively or near-exclusively on target therapeutics
development.
More Trending Reports by Transparency Market Research:
About Us
Transparency Market Research (TMR) is a market intelligence
company, providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use proprietary
data sources and various tools and techniques to gather and analyze
information. Our business offerings represent the latest and the most reliable
information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different
sector - such as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These reports
provide in-depth analysis and deep segmentation to possible micro levels. With
wider scope and stratified research methodology, TMR’s syndicated reports
thrive to provide clients to serve their overall research requirement.
Contact
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
